skip to content
Clinical review report. Brexpiprazole (Rexulti) : (Lundbeck Canada Inc. and Otsuka Canada Pharmaceutical Inc.) : indication: treatment of schizophrenia in adults. Preview this item
ClosePreview this item
Checking...

Clinical review report. Brexpiprazole (Rexulti) : (Lundbeck Canada Inc. and Otsuka Canada Pharmaceutical Inc.) : indication: treatment of schizophrenia in adults.

Author: Canadian Agency for Drugs and Technologies in Health,
Publisher: [Ottawa, Ontario] : Canadian Agency for Drugs and Technologies in Health, December 2017.
Series: Common drug review clinical review report.
Edition/Format:   eBook : Document : English
Summary:
Brexpiprazole is an atypical antipsychotic drug indicated for the treatment of schizophrenia in adults. The product monograph states that the efficacy of brexpiprazole is thought to be mediated through partial agonist activity at serotonergic 5-HT1A and dopaminergic D2 receptors, and antagonist activity at serotonergic 5-HT2A receptors. The recommended dosage is 2 mg to 4 mg once daily. The product monograph  Read more...
Rating:

(not yet rated) 0 with reviews - Be the first.

Subjects
More like this

Find a copy online

Links to this item

Find a copy in the library

&AllPage.SpinnerRetrieving; Finding libraries that hold this item...

Details

Genre/Form: Systematic Review
Table
Material Type: Document, Internet resource
Document Type: Internet Resource, Computer File
All Authors / Contributors: Canadian Agency for Drugs and Technologies in Health,
OCLC Number: 1089416278
Notes: "Version: final with redactions."
Description: 1 online resource (1 PDF file (155 pages)) : illustrations.
Series Title: Common drug review clinical review report.
Other Titles: Brexpiprazole (Rexulti) :
Clinical review report for Rexulti

Abstract:

Brexpiprazole is an atypical antipsychotic drug indicated for the treatment of schizophrenia in adults. The product monograph states that the efficacy of brexpiprazole is thought to be mediated through partial agonist activity at serotonergic 5-HT1A and dopaminergic D2 receptors, and antagonist activity at serotonergic 5-HT2A receptors. The recommended dosage is 2 mg to 4 mg once daily. The product monograph recommends a starting dosage of 1 mg per day on days 1 to 4, titrated to 2 mg once daily on days 5 to 7, and then to 4 mg on day 8, based on the patient's clinical response and tolerability. The maximum recommended daily dosage is 4 mg for most patients. The manufacturer has requested that brexpiprazole be reimbursed in accordance with the Health Canada-approved indication (i.e., for the treatment of schizophrenia in adults).

Reviews

User-contributed reviews
Retrieving GoodReads reviews...
Retrieving DOGObooks reviews...

Tags

Be the first.
Confirm this request

You may have already requested this item. Please select Ok if you would like to proceed with this request anyway.

Linked Data


Primary Entity

<http://www.worldcat.org/oclc/1089416278> # Clinical review report. Brexpiprazole (Rexulti) : (Lundbeck Canada Inc. and Otsuka Canada Pharmaceutical Inc.) : indication: treatment of schizophrenia in adults.
    a schema:Book, schema:CreativeWork, schema:MediaObject ;
    library:oclcnum "1089416278" ;
    library:placeOfPublication <http://id.loc.gov/vocabulary/countries/onc> ;
    schema:about <http://experiment.worldcat.org/entity/work/data/8961820723#Topic/treatment_outcome> ; # Treatment Outcome
    schema:about <http://experiment.worldcat.org/entity/work/data/8961820723#Topic/schizophrenia_drug_therapy> ; # Schizophrenia--drug therapy
    schema:about <http://experiment.worldcat.org/entity/work/data/8961820723#Topic/antipsychotic_agents_administration_&_dosage> ; # Antipsychotic Agents--administration & dosage
    schema:about <http://experiment.worldcat.org/entity/work/data/8961820723#Place/canada> ; # Canada.
    schema:about <http://experiment.worldcat.org/entity/work/data/8961820723#Topic/quinolones_therapeutic_use> ; # Quinolones--therapeutic use
    schema:about <http://experiment.worldcat.org/entity/work/data/8961820723#Topic/thiophenes_therapeutic_use> ; # Thiophenes--therapeutic use
    schema:alternateName "Clinical review report for Rexulti" ;
    schema:alternateName "Brexpiprazole (Rexulti) :" ;
    schema:bookFormat schema:EBook ;
    schema:contributor <http://experiment.worldcat.org/entity/work/data/8961820723#Organization/canadian_agency_for_drugs_and_technologies_in_health> ; # Canadian Agency for Drugs and Technologies in Health,
    schema:datePublished "2017" ;
    schema:description "Brexpiprazole is an atypical antipsychotic drug indicated for the treatment of schizophrenia in adults. The product monograph states that the efficacy of brexpiprazole is thought to be mediated through partial agonist activity at serotonergic 5-HT1A and dopaminergic D2 receptors, and antagonist activity at serotonergic 5-HT2A receptors. The recommended dosage is 2 mg to 4 mg once daily. The product monograph recommends a starting dosage of 1 mg per day on days 1 to 4, titrated to 2 mg once daily on days 5 to 7, and then to 4 mg on day 8, based on the patient's clinical response and tolerability. The maximum recommended daily dosage is 4 mg for most patients. The manufacturer has requested that brexpiprazole be reimbursed in accordance with the Health Canada-approved indication (i.e., for the treatment of schizophrenia in adults)."@en ;
    schema:exampleOfWork <http://worldcat.org/entity/work/id/8961820723> ;
    schema:genre "Table"@en ;
    schema:genre "Systematic Review"@en ;
    schema:inLanguage "en" ;
    schema:isPartOf <http://experiment.worldcat.org/entity/work/data/8961820723#Series/cadth_common_drug_review> ; # CADTH common drug review
    schema:isPartOf <http://experiment.worldcat.org/entity/work/data/8961820723#Series/common_drug_review_clinical_review_report> ; # Common drug review clinical review report.
    schema:name "Clinical review report. Brexpiprazole (Rexulti) : (Lundbeck Canada Inc. and Otsuka Canada Pharmaceutical Inc.) : indication: treatment of schizophrenia in adults."@en ;
    schema:productID "1089416278" ;
    schema:url <http://www.ncbi.nlm.nih.gov/books/NBK535498/> ;
    wdrs:describedby <http://www.worldcat.org/title/-/oclc/1089416278> ;
    .


Related Entities

<http://experiment.worldcat.org/entity/work/data/8961820723#Organization/canadian_agency_for_drugs_and_technologies_in_health> # Canadian Agency for Drugs and Technologies in Health,
    a schema:Organization ;
    schema:name "Canadian Agency for Drugs and Technologies in Health," ;
    .

<http://experiment.worldcat.org/entity/work/data/8961820723#Series/cadth_common_drug_review> # CADTH common drug review
    a bgn:PublicationSeries ;
    schema:hasPart <http://www.worldcat.org/oclc/1089416278> ; # Clinical review report. Brexpiprazole (Rexulti) : (Lundbeck Canada Inc. and Otsuka Canada Pharmaceutical Inc.) : indication: treatment of schizophrenia in adults.
    schema:name "CADTH common drug review" ;
    .

<http://experiment.worldcat.org/entity/work/data/8961820723#Series/common_drug_review_clinical_review_report> # Common drug review clinical review report.
    a bgn:PublicationSeries ;
    schema:hasPart <http://www.worldcat.org/oclc/1089416278> ; # Clinical review report. Brexpiprazole (Rexulti) : (Lundbeck Canada Inc. and Otsuka Canada Pharmaceutical Inc.) : indication: treatment of schizophrenia in adults.
    schema:name "Common drug review clinical review report." ;
    .

<http://experiment.worldcat.org/entity/work/data/8961820723#Topic/antipsychotic_agents_administration_&_dosage> # Antipsychotic Agents--administration & dosage
    a schema:Intangible ;
    schema:name "Antipsychotic Agents--administration & dosage"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/8961820723#Topic/quinolones_therapeutic_use> # Quinolones--therapeutic use
    a schema:Intangible ;
    schema:name "Quinolones--therapeutic use"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/8961820723#Topic/schizophrenia_drug_therapy> # Schizophrenia--drug therapy
    a schema:Intangible ;
    schema:name "Schizophrenia--drug therapy"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/8961820723#Topic/thiophenes_therapeutic_use> # Thiophenes--therapeutic use
    a schema:Intangible ;
    schema:name "Thiophenes--therapeutic use"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/8961820723#Topic/treatment_outcome> # Treatment Outcome
    a schema:Intangible ;
    schema:name "Treatment Outcome"@en ;
    .

<http://www.worldcat.org/title/-/oclc/1089416278>
    a genont:InformationResource, genont:ContentTypeGenericResource ;
    schema:about <http://www.worldcat.org/oclc/1089416278> ; # Clinical review report. Brexpiprazole (Rexulti) : (Lundbeck Canada Inc. and Otsuka Canada Pharmaceutical Inc.) : indication: treatment of schizophrenia in adults.
    schema:dateModified "2019-03-09" ;
    void:inDataset <http://purl.oclc.org/dataset/WorldCat> ;
    .


Content-negotiable representations

Close Window

Please sign in to WorldCat 

Don't have an account? You can easily create a free account.